DDX21 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 23 Jul 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antiviral Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for DDX21 drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen DDX21 Full-Length & Active Domain Recombinant Protein
Full-length (1–895 aa) containing DEAD-box domain and isolated helicase core. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified.		 View DDX21 Products
Gene Delivery DDX21 Promise-ORF / Lentivirus
Full-length ORF for stable cell lines.		 View DDX21 Products
Benchmark Ab Anti-DDX21 Antibody
Recombinant positive control for assay validation.		 View DDX21 Products
Validator DDX21 siRNA Set
For knockdown verification in cellular assays.		 View DDX21 Products
Selectivity Panel – DDX5 (p68) Closest paralog for counter-screening. High purity (>95%), Sequence Verified. View DDX5 Products
Pathway Partner – DDX3X DEAD-box family member for pan-helicase counter-screening. Endotoxin controlled. View DDX3X Products
Pathway Partner – RIG-I (DDX58) Synergistic innate immune viral sensing pathway. View RIG-I Products
Pathway Partner – DDX41 Innate immunity axis synergy; STING pathway cross-talk. View DDX41 Products
Functional Partner – POLR1A RNA Polymerase I largest subunit, ribosome biogenesis complex. View POLR1A Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
DEAD-box Family Off-target Activity Homolog panel proteins (DDX5, DDX3X, DDX41, RIG-I) strictly verified by mass spec and sequence analysis; matched expression systems for direct comparison.
Intracellular Protein Instability / Soluble Expression Optimized expression tags and precise theoretical MW validation for robust biochemical assays. Full-length and domain constructs available.
Lack of Genetic Controls DDX21 siRNA Set and Lentivirus-ORF included for knockdown/rescue specificity checks.
False Positives in Knockdown Studies / TLR Interference Validated siRNA for specificity checks; Endotoxin-controlled batch release (<1 EU/µg) to minimize confounding activation in immune cell lines.
Structural Biology (Crystallography) Domain-truncated variants (ATP-binding cassette) available, high solubility HEK293 expression.

Live DDX21 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

DDX21 is an emerging drug target positioned at the intersection of ribosome biogenesis and innate immunity. While no late-stage clinical candidates have advanced to Phase II/III, preclinical data from academic and discovery-stage biotech programs highlight its dual role in promoting tumor cell proliferation (via rRNA biogenesis and c-Jun regulation) and modulating antiviral innate immunity. The target is gaining traction as a synthetic lethal vulnerability in tumors with elevated ribosomal stress, including MYC-driven malignancies, and as a broad-spectrum antiviral host factor. Current R&D is driven by three dominant modalities: small-molecule inhibitors (ATP-competitive and allosteric), PROTAC degraders, and RNA-targeted therapies (siRNA/ASO/CRISPR). The next wave of R&D is expected to shift from tool-compound generation to selective helicase inhibitors that exploit DDX21's nucleolar localization and ATP-dependent conformational cycles, with allosteric modulation and targeted protein degradation (PROTACs) bypassing the poor selectivity traditionally associated with ATP-competitive inhibitors. Future directions also include combination therapies with ribosomal stress-inducing agents and immune checkpoint inhibitors.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule Inhibitors (ATP-competitive & Allosteric) Early-stage Biotech / Academia Solid Tumors (Breast, Prostate, Colorectal, Lung), Hematologic Malignancies ATPase/Helicase assay (Need high-purity full-length & domain proteins; selectivity panel for off-target screening)
PROTACs / Degraders Emerging Biotech Platforms Refractory Solid Tumors, Cancers with helicase addiction Ternary complex validation (Need lentivirus ORF, siRNA for cell line construction; paralog panel for selectivity)
RNA-targeted Therapies (siRNA/ASO/CRISPR) RNA Therapeutics Companies / Academic Consortia Viral Infections, Oncology Knockdown validation (Need reliable siRNA sets, rescue ORF controls)